Cresco Labs Inc. Earnings Recaps
Q3 2025
Nov 7, 2025
Cresco Labs reported a modest revenue growth of 1% to $165 million in Q3 2025 while making strategic moves to strengthen the balance sheet and focus on core markets for sustainable growth.
Key takeaways
- Adjusted EBITDA reached $40 million, reflecting disciplined execution and a focus on cash-generating operations.
- Completed debt refinancing, enhancing financial flexibility and positioning for future investments and M&A opportunities.
- Exited California operations, reducing liabilities and organizational complexity to concentrate on more profitable ventures.
- Maintained #1 retail share in Ohio with successful new dispensary openings planned for early 2026, while preparing to enter Kentucky's medical market.
- Set to launch flagship Cresco branded products in Germany, marking the company's entry into the European Union market.